Corgenix Medical announced completion of a major phase of the collaborative effort to combat important viral diseases. The multi-year study, conducted primarily at the Kenema Government Hospital in Kenema, Sierra Leone, is investigating the clinical utility of several diagnostic products developed by Corgenix and other members of the Viral Hemorrhagic Fever Consortium, a collaboration of academic and industry members headed by Tulane University. In this major study, scientists are using consortium-developed recombinant antigen-based tests to evaluate patients presenting with clinical symptoms of Lassa hemorrhagic fever. Corgenix said that the first of the products used in the studies, the ReLASV Antigen Rapid Test, will be advanced into full commercialization this year. Corgenix has submitted the study results to secure CE Marking, a regulatory requirement in Europe and many other countries.